Inpatient and Outpatient Orderable

Atypical Hemolytic Uremic Syndrome (AHUS) Complement Panel

Synonyms

  • ATYPICAL HEMOLYTIC UREMIC SYNDROME COMPLEMENT P
  • LAB11038

Cerner Name

aHUS Complement Panel, S and P

Clinical Info

Detecting deficiencies in the alternative pathway that can cause atypical-hemolytic uremic syndrome, dense deposit disease, and C3 glomerulonephritis

ORDERING GUIDANCE
This test should be performed prior to treatment initiation and in the absence of therapy with complement inhibitors, such as eculizumab or ravulizumab. Complement inhibitors will affect performance of these assays.

For evaluating patients with possible thrombotic microangiopathies (TMA), the recommended first-tier test is ADM13 / ADAMTS13 Activity and Inhibitor Profile, Plasma. This test should be a second-tier test for TMA.

For patients who have received eculizumab or need to monitor response to eculizumab therapy, the recommended test is ECUMP / Eculizumab Monitoring Panel, Serum. Soluble membrane attack complex (sMAC) should not be used as a standalone assay to monitor eculizumab efficiency.

Specimen Sources

Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

Blood

Container

Lavender Top Tube

Collection Instructions

Serum and Plasma are required for this test
Container/Tube: Both Lavender Top  AND Red Top Tube
Specimen: 1.5 mL EDTA plasma ( 1.5 mL min) AND 1.5 mL serum (1.5 mL min)
Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. Centrifuge; 1500 x g for 10 minutes at 4 degrees C and aliquot plasma from Lavender tube and serum from the Red tube into plastic vial.
3. Freeze specimen within 30 minutes.

Patient Preparation:
1. Fasting preferred.
2. Samples should not be collected earlier than 48 hours following plasma exchange.
Alternate Tube:
Plasma :  Light Blue (3.3 % sodium citrate)
Serum Gold Top Tube

Specimen Volume

Transport Instructions

Frozen

Specimen Stability

Plasma 14 Days Frozen
Serum Red 14 Days Frozen

Methodology

Nephelometry
Automated Liposome Lysis Assay
Enzyme-Linked Immunosorbent Assay (ELISA)

Days Performed

TAT: 13 - 22 Days

Performing Laboratory

Mayo Medical Laboratories

CPT

86160 x 6
86161
86162

PDM

225440

Only Orderable at Locations:

Orderable Everywhere

Results
Component Name Base Name Common Name External Name
ATYPICAL HEMOLYTIC UREMIC SYNDROME INTERPRETATION AHUSINT ATYPICAL HEMOLYTIC UREMIC SYNDROME INTERPRETATION AHUS Interpretation
IS ECULIZUMAB OR RAVULIZUMAB TAKEN? MEDTAKEN IS ECULIZUMAB OR RAVULIZUMAB TAKEN Is Eculizumab or Ravulizumab taken?
COMPLEMENT, TOTAL, S COMTOTS COMPLEMENT, TOTAL, S Complement, Total, S
ALTERNATIVE COMPLEMENT PATH FUNC, S ALTCOMPPATH ALTERNATIVE COMPLEMENT PATH FUNC, S Alternative Complement Path Func, S
COMPLEMENT C3, S C3COMP COMPLEMENT C3, S Complement C3, S
COMPLEMENT C4, S C4COMP COMPLEMENT C4, S Complement C4, S
FACTOR B COMPLEMENT ANTIGEN, S FACTORB FACTOR B COMPLEMENT ANTIGEN, S Factor B Complement Antigen, S
FACTOR H COMPLEMENT ANTIGEN, S FACTORH FACTOR H COMPLEMENT ANTIGEN, S Factor H Complement Antigen, S
CBB COMPLEMENT, P CBBCOMP CBB COMPLEMENT, P CBb Complement, P
SC5B-9 COMPLEMENT, P SC5B9CO SC5B 9 COMPLEMENT, P SC5b-9 Complement, P

Result Interpretation

FACTOR B COMPLEMENT ANTIGEN     15.2-42.3 mg/dL

SC5b-9 COMPLEMENT                          < or =250 ng/mL

FACTOR H COMPLEMENT ANTIGEN      18.5 to 40.8 mg/dL

CBb COMPLEMENT ACTIVATION FRAGMENT   < or =1.6 mcg/mL

COMPLEMENT C4                                    14-40 mg/dL

COMPLEMENT C3                                    75-175 mg/dL

ALTERNATIVE COMPLEMENT, PATHWAY (AH50) FUNCTIONAL

                                                              > or =46% Normal

COMPLEMENT, TOTAL                             30-75 U/mL

 

 

Forms
LAB11038 build edit